Fibroblast-mediated collagen remodeling within the tumor microenvironment facilitates progression of thyroid cancers driven by brafv600e and pten loss

Cancer Research

Volumn 76, Issue 7, 2016, Pages 1804-1813

  Jolly, Lee Ann ^a   Novitskiy, Sergey ^b   Owens, Phillip ^b   Massoll, Nicole ^c   Cheng, Nikki ^d   Fang, Wei ^d   Moses, Harold L ^b   Franco, Aime T ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; COLLAGEN TYPE 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN LYSINE 6 OXIDASE; COLLAGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CANCER ASSOCIATED FIBROBLAST; CELL MIGRATION; CELL PROLIFERATION; COL1A1 GENE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LOX GENE; MAJOR CLINICAL STUDY; MOUSE; MOUSE MODEL; NONHUMAN; ONCOGENE H RAS; OVERALL SURVIVAL; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PTEN GENE; THYROID CANCER; THYROID CANCER CELL LINE; THYROID PAPILLARY CARCINOMA; TUMOR MICROENVIRONMENT; UPREGULATION; GENETICS; METABOLISM; PATHOLOGY; THYROID TUMOR;

CELL PROLIFERATION; COLLAGEN; FIBROBLASTS; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84963541073     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2351     Document Type: Article

References (50)

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014;74:2913-21.
2. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7:569-80.
3. Are C, Shaha AR. Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.
4. Ricarte-Filho JC, RyderM, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary andmetastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-93.
5. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;65:10199-207.
6. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharmacol 2010;80:592-601.
7. Krajewska J,Handkiewicz-JunakD, Jarzab B. Sorafenib for the treatment of thyroid cancer: An updated review. Expert Opinion on Pharmacother 2015;16:573-83.
8. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-20.
9. Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 2012;196:395-406.
10. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: Tumor-associated niche cells. Gen Devel 2008;22:559-74.
11. Madar S, Goldstein I, Rotter V. 'Cancer associated fibroblasts'-more than meets the eye. Trends Mol Med 2013;19:447-53.
12. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6: 392-401.
13. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.
14. Yamaguchi H, Yoshida N, Takanashi M, Ito Y, Fukami K, Yanagihara K, et al. Stromal fibroblasts mediate extracellular matrix remodeling and invasion of scirrhous gastric carcinoma cells. PloS One 2014;9:e85485.
15. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res 2012;10:1403-18.
16. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumorassociated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116:1955-62.
17. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004;10:7427-37.
18. Zou X, Feng B, Dong T, Yan G, Tan B, Shen H, et al. Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics 2013;94:473-85.
19. Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol 1998;186:262-8.
20. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Gen 2003;33:49-54.
21. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
22. Ryschich E, Khamidjanov A, Kerkadze V, Buchler MW, Zoller M, Schmidt J. Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer. Pancreas 2009;38:804-10.
23. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008;6:11.
24. Shintani Y, Maeda M, Chaika N, Johnson KR, Wheelock MJ. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Resp Cell Mol Biol 2008; 38:95-104.
25. Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, et al. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. PNAS 2011;108:1615-20.
26. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res 2009; 69:3689-94.
27. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGFalpha-, MSP-and HGF-mediated signaling networks. Oncogene 2005; 24:5053-68.
28. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. BioTechniques 2002;32:1372-4, 76, 78-9.
29. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
30. Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KGJr, et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 2006;12:1983-93.
31. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1.
32. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
33. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-16.
34. Shingu K, Fujimori M, Ito K, Hama Y, Kasuga Y, Kobayashi S, et al. Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: Difference between neoplasms and hyperplastic lesions. Endocrine J 1998;45:35-43.
35. Pasieka Z, Stepien H, Komorowski J, Kolomecki K, Kuzdak K. Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer. Recent Results in Cancer Research Fortschritte Der Krebsforschung Progres dans les recherches sur le cancer 2003;162:189-94.
36. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146:1145-53.
37. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010;141:52-67.
38. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139:891-906.
39. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440: 1222-6.
40. Boufraqech M, Nilubol N, Zhang L, Gara SK, Sadowski SM, Mehta A, et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Res 2015;75:367-77.
41. Yarchoan M, LiVolsi VA, Brose MS. BRAF mutation and thyroid cancer recurrence. J Clin Oncol 2015;33:7-8.
42. Mbeunkui F, Johann DJJr. Cancer and the tumor microenvironment: A reviewof an essential relationship. Cancer Chemother Pharmacol 2009;63: 571-82.
43. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocrine Rev 2007;28: 742-62.
44. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, et al. B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 2010;107:10649-54.
45. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. Tumorderived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012;21:822-35.
46. Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 2006;25:2105-12.
47. Whipple CA, Brinckerhoff CE. BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity. Br J Cancer 2014;111:1625-33.
48. Ng MR, Brugge JS. Astiff blow from the stroma: Collagen crosslinking drives tumor progression. Cancer Cell 2009;16:455-7.
49. Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas. Cancer Res 2013;73:5336-46.
50. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and themalignant phenotype. Cancer Cell 2005;8: 241-54.